Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Triamcinolone and Bevacizumab for Diabetic Retinopathy
NCT00806169Phase 3Completed
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Apr 2006
- Primary completion
- Oct 2008
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label trial of triamcinolone and bevacizumab in diabetic macular edema (DME) (3 arms), sponsored by Universitätsklinikum Frankfurt. Primary endpoint: Best Corrected Visual Acuity. Started Apr 2006; status: completed.
02
Drugs
triamcinolonebevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00806169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00806169.